Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Garches – page 118

3 430 clinical trials in Garches, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Garches at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Garches

Open in trial search

Epidermolysis bullosa

Not yet recruiting

Assessing the efficacy and safety of nemolizumab in patients aged 12 years or older with dystrophic epidermolysis bullosa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Atrial fibrillation+1

Not yet recruiting

Landiolol hydrochloride to prevent new‑onset atrial fibrillation after heart surgery in Caucasian patients undergoing cardiopulmonary bypass

Registered drug
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Sodium Chloride
  • Sponsor:GCS Ramsay Sante Enseignement Et Recherche

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Mucormycosis

Not yet recruiting

Efficacy of isavuconazonium sulfate and amphotericin B drug combination for initial treatment of mucormycosis in adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Assistance Publique Hopitaux De Paris

Phase II trial evaluating trastuzumab deruxtecan in patients with HER2‑positive advanced/metastatic cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Centre Leon Berard

Renal transplant

Not yet recruiting

Efficacy of daily high‑dose sulfamethoxazole‑trimethoprim prophylaxis versus low‑dose on bacterial infections in kidney transplant recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sulfamethoxazole
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Garches

What the registry says about research in the country

01 Neurological Disorders

Clinical trials focusing on innovative treatments for neuromuscular conditions and movement disorders, including studies on Spinal Muscular Atrophy and Myasthenia Gravis. Research examines novel drug delivery systems and therapeutic approaches for improving patient outcomes.

  • Spinal Muscular Atrophy Treatment
  • Myasthenia Gravis Management
  • Myotonic Dystrophy Research
02 Critical Care Medicine

Groundbreaking research in intensive care focusing on treating severe conditions like septic shock and immunosuppression. Studies evaluate new therapeutic approaches for improving survival rates and patient outcomes in critical care settings.

  • Sepsis Treatment Innovations
  • Immune System Support
  • Critical Care Interventions
03 Rare Diseases

Innovative clinical trials targeting rare genetic conditions including Pompe Disease and Fabry Disease. Research focuses on enzyme replacement therapies and novel treatment approaches to improve patient quality of life.

  • Enzyme Replacement Therapy
  • Genetic Disease Management
  • Pediatric Rare Disease Treatment
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.